These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 29894679)

  • 21. Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson's Disease.
    Nguyen M; Wong YC; Ysselstein D; Severino A; Krainc D
    Trends Neurosci; 2019 Feb; 42(2):140-149. PubMed ID: 30509690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Molecular basis of Parkinson's disease linked with mutations in the LRRK2 gene].
    Pchelina SN; emel'ianov AK; Usenko TS
    Mol Biol (Mosk); 2014; 48(1):3-14. PubMed ID: 25842821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreased Sirtuin Deacetylase Activity in LRRK2 G2019S iPSC-Derived Dopaminergic Neurons.
    Schwab AJ; Sison SL; Meade MR; Broniowska KA; Corbett JA; Ebert AD
    Stem Cell Reports; 2017 Dec; 9(6):1839-1852. PubMed ID: 29129681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LRRK2 at the interface of autophagosomes, endosomes and lysosomes.
    Roosen DA; Cookson MR
    Mol Neurodegener; 2016 Dec; 11(1):73. PubMed ID: 27927216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LRRK2 signaling in neurodegeneration: two decades of progress.
    Iannotta L; Greggio E
    Essays Biochem; 2021 Dec; 65(7):859-872. PubMed ID: 34897411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LRRK2 links genetic and sporadic Parkinson's disease.
    Kluss JH; Mamais A; Cookson MR
    Biochem Soc Trans; 2019 Apr; 47(2):651-661. PubMed ID: 30837320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
    Büeler H
    Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease.
    Verma M; Steer EK; Chu CT
    Biochim Biophys Acta; 2014 Aug; 1842(8):1273-81. PubMed ID: 24225420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition.
    Smith GA; Jansson J; Rocha EM; Osborn T; Hallett PJ; Isacson O
    Mol Neurobiol; 2016 Oct; 53(8):5161-77. PubMed ID: 26399642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of LRRK2 in Intracellular Organelle Dynamics.
    Boecker CA
    J Mol Biol; 2023 Jun; 435(12):167998. PubMed ID: 36764357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional Impairment in Miro Degradation and Mitophagy Is a Shared Feature in Familial and Sporadic Parkinson's Disease.
    Hsieh CH; Shaltouki A; Gonzalez AE; Bettencourt da Cruz A; Burbulla LF; St Lawrence E; Schüle B; Krainc D; Palmer TD; Wang X
    Cell Stem Cell; 2016 Dec; 19(6):709-724. PubMed ID: 27618216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration.
    Jeong GR; Jang EH; Bae JR; Jun S; Kang HC; Park CH; Shin JH; Yamamoto Y; Tanaka-Yamamoto K; Dawson VL; Dawson TM; Hur EM; Lee BD
    Mol Neurodegener; 2018 Feb; 13(1):8. PubMed ID: 29439717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease.
    Ito G; Utsunomiya-Tate N
    Biomolecules; 2023 May; 13(5):. PubMed ID: 37238714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LRRK2 Structure-Based Activation Mechanism and Pathogenesis.
    Zhang X; Kortholt A
    Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling Parkinson's disease in LRRK2 mice: focus on synaptic dysfunction and the autophagy-lysosomal pathway.
    Albanese F; Domenicale C; Volta M; Morari M
    Biochem Soc Trans; 2022 Feb; 50(1):621-632. PubMed ID: 35225340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a physiologically relevant and easily scalable LUHMES cell-based model of G2019S LRRK2-driven Parkinson's disease.
    Calamini B; Geyer N; Huss-Braun N; Bernhardt A; Harsany V; Rival P; Cindhuchao M; Hoffmann D; Gratzer S
    Dis Model Mech; 2021 Jun; 14(6):. PubMed ID: 34114604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The parkinson's disease-associated LRRK2 mutation R1441G inhibits neuronal differentiation of neural stem cells.
    Bahnassawy L; Nicklas S; Palm T; Menzl I; Birzele F; Gillardon F; Schwamborn JC
    Stem Cells Dev; 2013 Sep; 22(18):2487-96. PubMed ID: 23600457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization.
    Papkovskaia TD; Chau KY; Inesta-Vaquera F; Papkovsky DB; Healy DG; Nishio K; Staddon J; Duchen MR; Hardy J; Schapira AH; Cooper JM
    Hum Mol Genet; 2012 Oct; 21(19):4201-13. PubMed ID: 22736029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular Pathways Involved in LRRK2-Linked Parkinson's Disease: A Systematic Review.
    Ravinther AI; Dewadas HD; Tong SR; Foo CN; Lin YE; Chien CT; Lim YM
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of tyrosine hydroxylase-dopamine pathway in Parkinson's disease pathogenesis.
    Zhou ZD; Saw WT; Ho PGH; Zhang ZW; Zeng L; Chang YY; Sun AXY; Ma DR; Wang HY; Zhou L; Lim KL; Tan EK
    Cell Mol Life Sci; 2022 Nov; 79(12):599. PubMed ID: 36409355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.